IP Library Granted Patent US 7,375,216
Granted Patent B2
US 7,375,216 · App. 10/812,156 · Granted May 20, 2008

Preparation of metal mesoporphyrin compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,375,216
App. No.
10/812,156
Granted
May 20, 2008
Kind
B2
Abstract

A method of preparing metal mesoporphyrin compounds is described. A metal mesoporphyrin compound may be formed by forming a novel mesoporphyrin IX intermediate compound and then converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. The novel intermediate compound may be formed by a catalytic hydrogenation of hemin in acid and subsequent recovery.

Claims (36)

1. A method of producing a metal mesoporphyrin compound comprising: isolating a mesoporphyrin formate; and converting the mesoporphyrin formate to a metal mesoporphyrin compound.

2. The method of claim 1 , wherein the mesoporphyrin formate is converted directly to the metal mesoporphyrin compound.

3. The method of claim 1 , wherein the mesoporphyrin formate is first converted to mesoporphyrin dihydrochloride and the mesoporphyrin dihydrochloride is converted to the metal mesoporphyrin compound.

4. The method of claim 3 , wherein the mesoporphyrin dihydrochloride is reacted with an insert metal to form the metal mesoporphyrin compound.

5. The method of claim 3 , further comprising purifying the mesoporphyrin formate in the presence of a metal scavenger.

6. The method of claim 5 , wherein the metal scavenger includes Si-thiol.

7. The method of claim 4 , further comprising catalytically hydrogenating hemin in the presence of an acid to form the mesoporphyrin formate.

8. The method of claim 7 , wherein the catalytic hydrogenation of the hemin occurs in two steps.

9. The method of claim 8 , further comprising heating a mixture of hemin and a hydrogenation catalyst under pressure at a first temperature for a first period of time and subjecting the mixture to a second temperature under pressure for a second period of time.

10. The method of claim 9 , wherein the first temperature is higher than the second temperature.

11. The method of claim 1 , wherein the metal mesoporphyrin compound is a metal mesoporphyrin halide.

12. The method of claim 10 , further comprising: a) subjecting a reaction mixture of hemin and a hydrogenation catalyst in an acid to hydrogen pressure of about 30-65 psi and then raising the temperature to about 85-95° C. and maintaining the temperature within that range for a period of about 1-3 hours; b) subjecting the reaction mixture to a further hydrogen pressure of about 30-65 psi at a temperature range of about 45-50° C. for a period of about 24-48 hours; and c) recovering the mesoporphyrin formate from the reaction mixture by precipitation of the mixture with a solvent.

13. The method of claim 7 , wherein the acid is formic acid.

14. The method of claim 12 , wherein the solvent is an ether.

15. The method of claim 14 , wherein the solvent is methyl tert-butyl ether.

16. The method of claim 15 , wherein the hydrogenation catalyst is palladium on carbon.

17. The method of claim 1 , wherein the quantity of metal mesoporphyrin compound formed by a single performance of the method exceeds 0.1 kg.

18. The method of claim 1 , further comprising purifying the metal mesoporphyrin compound, including: a) dissolving the metal mesoporphyrin compound in an aqueous basic solution to obtain a dissolved metal mesoporphyrin compound; b) treating said dissolved metal mesoporphyrin compound with charcoal to obtain a treated metal mesoporphyrin compound; c) adding said treated metal mesoporphyrin compound to a first aqueous acid solution to obtain a precipitated metal mesoporphyrin compound; d) triturating said precipitated metal mesoporphyrin halide in a second aqueous acid solution at elevated temperature to obtain a substantially pure metal mesoporphyrin compound; and e) drying said substantially pure metal mesoporphyrin compound.

19. The method of claim 18 , wherein the metal mesoporphyrin halide is tin (IV) mesoporphyrin IX dihydrochloride.

20. The method of claim 19 , further comprising reacting the mesoporphyrin IX dihydrochioride with tin to form tin (IV) mesoporphyrin IX dichioride.

21. The method of claim 1 , wherein the mesoporphyrin formate is isolated in substantially pure, solid form.

22. The method of claim 21 , wherein the mesoporphyrin formate is converted to mesoporphyrin IX dihydrochloride.

23. The method of claim 22 , further comprising reacting the mesoporphyrin IX dihydrochloride with tin to form tin (IV) mesoporphyrin IX dichioride.

24. The method of claim 23 , wherein the quantity of tin (IV) mesoporphyrin IX dichioride formed by a single performance of the method exceeds 0.1 kilograms.

25. The method of claim 21 , further comprising purifying the mesoporphyrin formate with a metal scavenger.

26. The method of claim 25 , wherein the metal scavenger includes a silica bound metal scavenger.

27. The method of claim 23 , further comprising purifying the tin (IV) mesoporphyrin IX dichioride includes trituration in hot acid at an elevated temperature.

28. The method of claim 27 , wherein the acid is HCl.

29. The method of claim 11 , wherein the metal mesoporphyrin halide is mesoporphyrin IX dihydrochloride.

30. The method of claim 18 , wherein the metal mesoporphyrin compound is a metal mesoporphyrin halide.

31. The method of claim 4 , wherein the mesoporphyrin dihydrochloride is reacted with the insert metal in the absence of any acetate ions.

32. The method of claim 23 , wherein the mesoporphyrin dihydrochioride is reacted with the tin in the absence of any acetate ions.

33. The method of claim 17 , wherein the quantity of metal mesoporphyrin compound formed by a single performance of the method exceeds 1 kg.

34. The method of claim 18 , wherein the quantity of metal mesoporphyrin compound formed by a single performance of the methods exceeds 1 kg.

35. The method of claim 23 , wherein the quantity of tin (IV) mesoporphyrin IX dichloride formed by a single performance of the methods exceeds 1 kg.

36. Tin (IV) mesoporphyrin IX dichioride produced by a single performance of the method of claim 23 .

Assignments (18)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044173, FRAME 0574 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0128 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0454 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049822/0674 →
NUNC PRO TUNC ASSIGNMENT Recorded May 24, 2019
From: INFACARE PHARMACEUTICAL CORPORATION
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 049274/0943 →
NUNC PRO TUNC ASSIGNMENT Recorded May 24, 2019
From: MALLINCKRODT IP UNLIMITED COMPANY
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 049274/0983 →
NUNC PRO TUNC ASSIGNMENT Recorded May 24, 2019
From: MALLINCKRODT PHARMA IP TRADING D.A.C.
To: MALLINCKRODT IP UNLIMITED COMPANY
Reel/Frame 049274/0954 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Oct 10, 2017
From: INFACARE PHARMACEUTICAL CORPORATION
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044173/0574 →
NAME ON AN ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED ON REEL 016309 FRAME 0340 RECORD TO CORRECT NAME OF ASSIGNOR Recorded Jul 27, 2006
From: WELLSPRING PHARMACEUTICAL CORPORATION
To: INFACARE PHARMACEUTICAL CORPORATION
Reel/Frame 018120/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2005
From: WELLSPRING CORPORATION
To: INFACARE PHARMACEUTICAL CORPORATION
Reel/Frame 016309/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2004
From: VUKOVICH, ROBERT; LEVINSON, BENJAMIN; DRUMMOND, GEORGE S.; CAROSELLI, ROBERT R.PH; ANTCZAK, KAZIMIERZ G.; BOUCHER, CHRISTOPHER; MORTIMER, RICHARD; LEVIN, DANNY; COOKE, KEITH A.
To: WELLSPRING PHARMACEUTICAL CORPORATION
Reel/Frame 014676/0402 →